<meta charset="utf8"></head><body>左心室負荷を伴う Ex vivo 灌流における心臓評価の強化

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>4- way Stopcock&#160;</td>
			<td>Smiths Medical&#160;</td>
			<td>MX9341L</td>
			<td></td>
		</tr>
		<tr>
			<td>4-0 Prolene sutures&#160;</td>
			<td>Ethicon&#160;</td>
			<td>8711</td>
			<td></td>
		</tr>
		<tr>
			<td>5-0 Suture</td>
			<td>Fine Scientific Tools</td>
			<td>18020-50</td>
			<td></td>
		</tr>
		<tr>
			<td>Aortic Connector&#160;</td>
			<td>VentriFLO Inc&#160;</td>
			<td></td>
			<td>Custom Made</td>
		</tr>
		<tr>
			<td>Aortic root cannula</td>
			<td>Medtronic Inc&#160;</td>
			<td>10012</td>
			<td></td>
		</tr>
		<tr>
			<td>Bovine Serum Albumin</td>
			<td>Sigma</td>
			<td>A7906</td>
			<td></td>
		</tr>
		<tr>
			<td>Calcium Chloride</td>
			<td>Sigma</td>
			<td>C7902</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell Saver&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>ATLG</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell Saver cartridges&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>ATLS00</td>
			<td></td>
		</tr>
		<tr>
			<td>Dextran</td>
			<td>Sigma</td>
			<td>31389</td>
			<td></td>
		</tr>
		<tr>
			<td>EKG epicardial leads&#160;</td>
			<td>VentriFLO Inc&#160;</td>
			<td></td>
			<td>Custom Made</td>
		</tr>
		<tr>
			<td>Equipment stand and brackets&#160;</td>
			<td>VentriFLO Inc&#160;</td>
			<td></td>
			<td>Custom Made</td>
		</tr>
		<tr>
			<td>External Pace maker&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>5392</td>
			<td></td>
		</tr>
		<tr>
			<td>Falcon High Clarity 50mL conical tubes</td>
			<td>Fisher Scientific</td>
			<td>14-432-22</td>
			<td></td>
		</tr>
		<tr>
			<td>Flow Probes&#160;</td>
			<td>TranSonic Sytems inc&#160;</td>
			<td>1828</td>
			<td></td>
		</tr>
		<tr>
			<td>Heparin sodium Injection</td>
			<td>Medplus</td>
			<td>G-0409-2720-0409-2721</td>
			<td></td>
		</tr>
		<tr>
			<td>Hollow fiber oxygenator and Venous&#160; Resevior</td>
			<td>Medtronic Inc&#160;</td>
			<td>BBP241</td>
			<td>Affinity Pixie, 1L</td>
		</tr>
		<tr>
			<td>HTP 1500&#160; Heat Therapy Pump</td>
			<td>HTP</td>
			<td>6826619</td>
			<td></td>
		</tr>
		<tr>
			<td>Insulin</td>
			<td>Humulin R</td>
			<td></td>
			<td>MGH Pharmacy</td>
		</tr>
		<tr>
			<td>Iworx Data Acquisition System</td>
			<td>Iworx</td>
			<td>IX-RA-834</td>
			<td></td>
		</tr>
		<tr>
			<td>Krebs-Henseleit Buffer</td>
			<td>Sigma</td>
			<td>K3753</td>
			<td></td>
		</tr>
		<tr>
			<td>Leukocyte Filter</td>
			<td>Haemonetics</td>
			<td>SB1E</td>
			<td></td>
		</tr>
		<tr>
			<td>Organ Chamber</td>
			<td>VentriFLO Inc&#160;</td>
			<td></td>
			<td>Custom Made</td>
		</tr>
		<tr>
			<td>Pacing Wires Biopolar</td>
			<td>Medtronic Inc&#160;</td>
			<td>6495</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin-Streptomycin</td>
			<td>ThermoFisher Scientific</td>
			<td>15140122</td>
			<td></td>
		</tr>
		<tr>
			<td>Pressure Trasnducers&#160;</td>
			<td>Iworx</td>
			<td>BP100</td>
			<td></td>
		</tr>
		<tr>
			<td>Pulsatile Pump</td>
			<td>VentriFLO Inc&#160;</td>
			<td>2100-0270</td>
			<td></td>
		</tr>
		<tr>
			<td>PVC Tubing&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>HY10Z49R9</td>
			<td></td>
		</tr>
		<tr>
			<td>Right Angle Metal Tip Cannula 20F</td>
			<td>Medtronic Inc&#160;</td>
			<td>67318</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium Bicarobonate</td>
			<td>Sigma</td>
			<td>5761</td>
			<td></td>
		</tr>
		<tr>
			<td>Standard PHD ULTRA CP Syringe Pump</td>
			<td>Harvard Aparatus</td>
			<td>88-3015</td>
			<td></td>
		</tr>
		<tr>
			<td>Tourniquet kit 7in&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>79006</td>
			<td></td>
		</tr>
		<tr>
			<td>Transonic Flow box</td>
			<td>TranSonic Sytems Inc&#160;</td>
			<td>T402</td>
			<td></td>
		</tr>
		<tr>
			<td>Venous Resevior&#160;</td>
			<td>Medtronic Inc&#160;</td>
			<td>CB841</td>
			<td>Affinity Fusion, 4L</td>
		</tr>
		<tr>
			<td>WIndKessel Bag</td>
			<td>VentriFLO Inc&#160;</td>
			<td></td>
			<td>Custom Made</td>
		</tr>
		<tr>
			<td>Y adapter</td>
			<td>Medtronic Inc&#160;</td>
			<td>10005</td>
			<td></td>
		</tr>
	</tbody>
</table>

cardiac loading using passive left atrial pressurization and passive afterload for graft assessment

Orthotopic heart transplantation is the current gold standard of care for end-stage heart failure1. Unfortunately, the field is significantly limited by a severe donor shortage crisis, resulting in only 2,000 heart transplants being performed each year when over 20,000 people would benefit from the lifesaving procedure2. This organ shortage is expected to worsen as the prevalence of heart failure in the United States alone is projected to surpass 8 million individuals by 20303. Steady increases in waitlist survival times - as a result of improved medical management, advances in mechanical circulatory support, and amendments to the UNOS allocation policy - have resulted in a further increase in the number of patients in need of transplantation at any given moment4,5.
Ex vivo machine perfusion or normothermic machine perfusion (NMP) is a preservation modality that has facilitated the expansion of the supply pool by allowing the use of organs donated after circulatory death (DCD) while achieving some extension of preservation times5,6,7,8. Unlike static cold storage, the current gold standard for preservation, NMP maintains organs in a metabolically active state, which creates the opportunity for real-time monitoring and graft assessment, becoming the standard preservation method for DCD grafts8,9. However, NMP devices currently used clinically are restricted to the Langendorff perfusion mode, which lacks quantitative metrics to predict transplantation outcomes and is unable to capture functional parameters6. For instance, lactate accumulation during Langendorff perfusion has been denoted as the best metabolic predictor of post-transplantation outcomes and is currently used in the clinical setting as a proxy for cardiac graft health10. However, even as the best assessment biomarker, it fails to reliably anticipate the need for mechanical circulatory support post-transplantation11,12. Similarly, the predictive capabilities of commonly utilized hemodynamic parameters (i.e., aortic pressure and coronary blood flow) are largely limited by the retrograde nature of current clinically used configurations for heart machine perfusion9.
The development of assessment protocols for accurate and precise determination of cardiac graft health during NMP would have an immense impact in the field beyond improving post-transplantation outcomes. Objective predictive tools would enable the reliable evaluation and likely utilization of marginal or extended criteria organs (i.e., prolonged warm (&#62; 30 min) and cold ischemia times (&#62; 6 h), increased donor age (&#62; 55), other comorbidities, etc.) from both DCD and brain death donors (DBD) that are currently rejected for transplantation due to the stringent selection criteria13. By enabling the use of marginal hearts, NMP could facilitate an increase in the organ supply as it is estimated that successful transplantation of half the hearts that currently go unused would be sufficient to eliminate the heart waitlist within 2-3 years14. Hemodynamic measurements obtained from left ventricular loading during NMP have garnered significant attention within the field due to their potential as objective assessment parameters. Previous studies have demonstrated that these parameters, such as left ventricular pulse pressure, contractility, and relaxation, are more indicative of cardiac graft function than metabolic trends15,16,17.
In effect, efforts have been dedicated to the development and identification of optimal loading methods to maximize assessment accuracy. Through these efforts, other groups have identified the most relevant mode of aortic perfusion during loading, whereby a stronger correlation between hemodynamic parameters and post-transplantation function was seen when implementing a passive afterload (i.e., no retrograde perfusion to the aorta during loading) when compared with pump-supported afterload (i.e., retrograde perfusion to the aorta during loading)18. This indicates that assisted coronary perfusion likely masks functional deficiencies. Previous studies have successfully incorporated passive afterloads into perfusion setups by implementing systems that mimic the Windkessel effect18,19,20. The Windkessel effect aids in dampening the fluctuation in blood pressure, maintaining continuous blood flow to the tissues and improving coronary perfusion. This protocol achieves the Windkessel-based passive afterload using a modified intravenous (IV) bag enclosed in two spring-loaded plates, where coronary perfusion is exclusively dependent on heart ejection (patent pending).
The use of passive left atrium (LA) pressurization (i.e., gravity-dependent pressurization) during loading, although common practice in small animal heart perfusions, is rarely utilized in the loading of large hearts21,22,23. Instead, the large majority of methods reported in the literature rely on secondary pumps for LA pressurization18,24,25,26,27,28. The pressurization of the LA through a gravity-dependent reservoir, rather than by pump, significantly simplifies the implementation of loading protocols. The use of gravity provides a fixed and constant pressure source, which greatly decreases the need for complicated control systems to achieve and maintain adequate LA pressurization. Moreover, through this pressurization approach, the requirement for a secondary pump is eliminated, facilitating the incorporation of loading capabilities into current Langerdoff setups, as only an extra reservoir is needed. The integration of loading capabilities into clinically utilized machine perfusion systems would amplify the application of cardiac NMP devices by facilitating detailed assessment of cardiac grafts during the preservation period. In effect, maximizing the utility of a system that poses significant financial commitment for patient care due to transportation and device utilization29.
This protocol demonstrates the feasibility of employing both passive afterload and passive LA pressurization during left ventricular loading. Through the validation of passive afterload/LA pressurization as a loading method, this protocol also provides an easy and effective manner of incorporating loading capabilities into established Langendorff perfusion systems. Importantly, it highlights the capability of functional assessment to uncover differences in viable versus failing hearts after extended periods of preservation (&#707;6 h).

<meta charset="utf8"></head><body>著者スポットライト:定量的指標と革新的な貯留層システムによるグラフト生存率評価の強化

移植片評価のための受動的左心房圧与と受動的後負荷を使用した心臓負荷

The scope of this research covers two important areas of cardiac ex vivo machine perfusion. First, it highlights the shortcomings of current clinically-used assessment metrics in determining graft viability and transplantability. Second, it provides an alternative assessment technique capable of discerning between viable and unviable grafts, even when conventional metrics fail to do so.Through this work, we developed a gravity-dependent loading reservoir that significantly simplifies and standardize the incorporation of loading capabilities into existing ex vivo machine perfusion systems. This, in combination with passive afterload, seems to significantly increase the predictive capabilities of the technique. The field has been in dire need of quantitative assessment metrics that eliminate the subjectivity of current practices.This work offers a method to obtain quantitative objective metrics for assessing graft variability. This assessment method is expected to significantly improve the ability to draw conclusions from both experimental and clinical setups.

Ex vivo machine perfusion or normothermic machine perfusion is a preservation method that has gained great importance in the transplantation field. ...

cardiac-loading-using-passive-left-atrial-pressurization-passive

Research

JoVE Journal

Medicine

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

314 ビュー.  Massachusetts General Hospital, Harvard Medical School. この研究の範囲は、心臓のex vivoマシン灌流の2つの重要な領域をカバーしています。まず、移植片の生存率と移植可能性を決定する際に現在臨床的に使用されている評価指標の欠点を強調しています。第二に、従来の指標がそうでない場合でも、生存可能な移植片と生存不可能な移植片を識別できる代替評価手法を提供します。この研究を?...